Study of KMV002 for prostate cancer that has spread and stopped responding to hormone treatment
This trial tests an investigational drug called KMV002 in men with prostate cancer that has spread to other parts of the body and is no longer controlled by hormone therapy. The goal is to see if the drug can help slow or stop the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man between 18 and 80 years old.
- Your prostate cancer must have spread beyond the prostate (metastatic) and be growing despite hormone treatment.
- You should have few or no symptoms from the cancer—for example, pain is controlled and you don't need immediate chemo or other treatments.
- You must have had certain types of hormone therapy in the past, or be able to switch to another one.
- You need to be generally healthy, with adequate blood cell counts, liver and kidney function, and be able to care for yourself.
- You must not have certain other cancers, infections (like HIV or active hepatitis), or medical conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a new drug called KTX-2001, possibly combined with another drug (darolutamide), for men whose prostate cancer has spread and stopped responding to standard hormone treatments. The goal is to see if it can help shrink tumors or slow the cancer's growth.
This trial tests VIR-5500 (AMX-500), a new targeted treatment, in men with prostate cancer that has spread and stopped responding to standard therapies. The goal is to see if it is safe and if it may help shrink or slow the cancer.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
Hear when a new Prostate Cancer Metastatic Castration-Resistant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.